Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. Issue 4 (October 2020)

• Record Type: Journal Article
• Authors: Cantini, Fabrizio; Niccoli, Laura; Nannini, Carlotta; Matarrese, Daniela; Natale, Massimo Edoardo Di; Lotti, Pamela; Aquilini, Donatella; Landini, Giancarlo; Cimolato, Barbara; Pietro, Massimo Antonio Di; Trezzi, Michele; Stobbione, Paolo; Frausini, Gabriele; Navarra, Assunta; Nicastri, Emanuele; Sotgiu, Giovanni; Goletti, Delia
• Is Part Of: Journal of infection. Volume 81:Issue 4(2020)
• Page Start: 647
• Page End: 679
• Publication Date: 2020-10
• Subjects: COVID-19 -- Baricitinib -- JAK1/2 -- Pneumonia -- Retrospective study -- SARS-Co-V2; Infection -- Periodicals; Bacterial Infections -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.905
• DOI: 10.1016/j.jinf.2020.06.052
• Languages: English
• ISSNs: 0163-4453

Abstract

Highlights: Baricitinib, an anti-JAK1/JAK2, reduces cytokine release and SARS-Co-V2 entry. In a retrospective multicenter study baricitinib reduces COVID-19 mortality rate. Baricitinib reduces intensive care unit admissions of COVID-19 pneumonia. Baricitinb reduces SARS-CoV-2 viral burden detected by nasopharyngeal swab. Baricitinib used for 2 weeks was not associated with serious adverse events. Graphical abstract: Image, graphical abstract